IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

Summary

One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..

Timeline

Start

2021-06-10

Primary completion

2021-10-07

Completion

2022-03-10

Drugs

Indications